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Abstract HIV reverse transcription is initiated from a cellular
tRNA partially associated with the retroviral genome. Here we
studied homologous HIV-2 cDNA synthesis using natural or
synthetic primers. With natural tRNALys3, synthesis of early
products comprising nucleotides +5 to +7 preceded the elonga-
tion step leading to synthesis of (3) strong-stop cDNA. In the
presence of a poly(A)Woligo(dT) trap, no full-length product was
observed while early products were still present, showing a
transition between initiation and elongation. With DNA primers
only an unspecific elongation was found. Our data show a similar
mechanism of reverse transcription initiation by HIV-1 and HIV-
2 reverse transcriptases. Furthermore, using a heterologous
system we found that HIV-1 RNA, in contrast to data reported
in the literature, was an excellent template for HIV-2 reverse
transcriptase.
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1. Introduction
In addition to its role in protein synthesis and several other
functions in various cellular processes, tRNA is crucial in
initiation of retroviral DNA synthesis. Human immunode¢-
ciency viruses type 1 and type 2 (HIV-1 and HIV-2) use the
same primer, cellular tRNALys3, to initiate reverse transcrip-
tion of the (3) strand of proviral DNA [1^3]. The replication
of HIV-2 has not been studied as extensively as that of HIV-1.
Most of the reported data concerning HIV-2 have been ob-
tained using synthetic primer/template complexes [4^6]. The
HIV-2 genome, besides being 451 nucleotides longer than
HIV-1 RNA, presents a higher complexity of its secondary
structure, most speci¢cally in the long terminal repeat
(LTR) regions. HIV-1 and HIV-2 isolates have about 61%
homology in the conserved gag and pol genes and 30^40%
of homology in their LTRs sequences [7]. Fig. 1 shows sche-
matically the secondary structure of the primer binding site
(PBS) region of HIV-2 determined using chemical and enzy-
matic approaches [8]. The secondary structure of the HIV-2
PBS domain is di¡erent from that of HIV-1 [9]. The PBS
seems more accessible in HIV-2 than in HIV-1: only three
out of 18 nucleotides are involved in a base pair, while in
the case of HIV-1, 12 out of 18 nucleotides are found in a
double stranded structure.
The annealing between tRNA and PBS prior to reverse
transcription implies interactions between two highly struc-
tured nucleic acids. Evidence, ¢rst reported in the case of
avian retroviruses, demonstrated that regions in the genomic
RNA other than the PBS interact with the primer tRNA.
Indeed, contacts between the T8C arm of the primer
tRNATrp and a region outside the avian retroviral PBS have
been proposed [10,11]. In this model, avian reverse transcrip-
tase (RT), tRNATrp and the RNA genomic template form a
complex in which the three components are maintained in a
speci¢c orientation allowing an e⁄cient initiation of reverse
transcription.
In HIV-1 several observations indicated that, in addition to
the 3P acceptor stem domain, other regions of tRNALys3 are
able to interact with HIV-1 viral RNA. Hybridization be-
tween an A-rich loop in the 5P region of the PBS and the
U-rich anticodon domain of primer tRNALys3 has been de-
scribed [12^14]. The importance of this interaction was also
shown in HIV-1 infected cells [15^17]. The HIV-1 A-rich re-
gion is placed in the U5 domain, close to the PBS, in a single
stranded region of a stem loop. Sequence analysis of the re-
gions around the PBS revealed a second A-rich cluster in 3P,
putatively capable of interacting with the anticodon of
tRNALys3 [18]. Lanchy et al. suggested that the functional
implication of this loop-loop interaction was to facilitate the
switch between the initiation and the elongation steps during
synthesis of the (3) cDNA strand [19]. In HIV-2 RNA four
consecutive A bases, partially single stranded (positions 287^
290 of HIV-2ROD RNA), are also present in the 5P region near
the PBS (see the empty black box in Fig. 1). This A-rich
region may be a good candidate for interacting with the anti-
codon domain of tRNALys3. Further studies of the interaction
between tRNALys3 and HIV-2 RNA are necessary to know if
similar secondary primer-template interactions as those de-
scribed for HIV-1 take place in the type 2 retrovirus.
Compared to HIV-1, very little is known concerning the
initiation of cDNA synthesis by HIV-2 RT using a tRNALys3
primer/HIV-2 RNA template duplex. Here, we studied HIV-2
reverse transcription initiation, and more speci¢cally the syn-
thesis of the cDNA early products. Natural and synthetic
forms of tRNALys3, as well as synthetic tDNALys3, were
used as primers of HIV-2 reverse transcription. Our results
showed a pattern of cDNA synthesis initiation similar to
HIV-1. Next we addressed the question whether HIV-2 RT
was able to reverse transcribe in a heterologous systems.
While it has been reported that only HIV-1, avian myeloblas-
tosis virus, and simian immunode¢ciency virus (SIV) RTs
were able to elongate tRNALys3 in the presence of HIV-1
RNA [20], we observed cDNA synthesis catalyzed by HIV-2
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RT from tRNALys3 on both HIV-1 and HIV-2 RNAs. Also,
reverse transcription from the natural tRNA was obtained
with HIV-1 RT on HIV-2 RNA.
2. Materials and methods
2.1. Materials
The pRT2 plasmid encoding the genes for the HIV-2 RT p68/p54
heterodimer (a kind gift of Prof. R. Goody, Max Planck Institute,
Dortmund, Germany) was expressed in Escherichia coli and puri¢ed
as previously described [21]. T7 RNA polymerase was from Strata-
gene, HincII and RNase-free DNase I from Gibco-BRL Life Tech-
nologies, and the human placental RNase inhibitor (RNasin) from
Promega. Natural tRNALys3 was puri¢ed from beef liver as already
described [22]; the puri¢ed tRNA showed an aminoacylation level of
1200^1600 pmol/A260 unit. In vitro synthetic tRNALys3 was prepared
by T7 RNA polymerase from the pLys plasmid which contains the
coding sequence (a kind gift from Dr. S.H. Wilson, North Carolina
[23]) under the control of the T7 bacteriophage promoter. Radioiso-
topes [K-32P]dATP (3000 Ci/mmol), [K-32P]dCTP (3000 Ci/mmol) and
[K-32P]CTP (3000 Ci/mmol) were purchased from Amersham (Buck-
inghamshire, UK). Unlabeled nucleotides and 1 kb DNA ladders were
from Gibco-BRL Life Technologies. Poly(A) and oligo(dT)12ÿ18 were
from Sigma. The synthetic primer/template duplex was prepared as
previously described [24].
2.2. In vitro HIV RNA synthesis
Plasmids pHIV-2 containing the nucleotides 1^545 from HIV-2ROD
strain and pmCG6 containing the fragment 1^4005 from HIV-1MAL
strain under the control of T7 promoter were a kind gift from Dr.
J.-L. Darlix, INSERM, Lyon, France. E. coli HB 101 (1035) rec A3
was used for plasmid ampli¢cation. After digestion of the HIV-2 clone
by NcoI (position 545) and of the HIV-1 clone by HincII (position
521), both were transcribed by T7 RNA polymerase. 3 Wg of linear-
ized plasmid DNA was transcribed in a ¢nal volume of 0.1 ml con-
taining 40 mM Tris-HCl (pH 8.0), 8 mM MgCl2, 10 mM spermidine,
25 mM NaCl, 10 mM dithiothreitol, 0.5 mM of each ribonucleoside
triphosphate, 100 units of T7 RNA polymerase and 20 units of pla-
cental ribonuclease inhibitor RNasin, for 1.5 h at 37‡C. After treat-
ment with 12 U of RNase-free DNase I for 10 min at 37‡C, RNA
transcripts were extracted with one volume of phenol/chloroform/iso-
amyl alcohol (24/24/1), then with one volume of chloroform and pre-
cipitated in 2.5 volumes of ethanol and 0.3 M ammonium acetate. The
size and the integrity of the RNAs were checked by UV light after
electrophoresis on a 1% agarose gel with ethidium bromide. RNA
fragments containing the ROD and MAL sequences start both at
position +1. Nucleotide sequences were checked and shown to be
identical with the original clones [8,25].
2.3. Reverse transcription assay
Reverse transcription was initiated by preincubation, in a ¢nal vol-
ume of 10 Wl containing 50 mM Tris-HCl (pH 8.0), 6 mM MgCl2,
2 mM dithiothreitol, 15 mM NaCl, 100 nM HIV-1 or HIV-2 RNA,
100 nM tRNALys3, 0.2 unit of RNasin and 150 nM HIV-2 or HIV-1
RT. With HIV-2 RNA as template, 5 WCi of [K-32P]dATP (3000 Ci/
mmol) was added, while [K-32P]dCTP (3000 Ci/mmol) was used with
HIV-1 RNA. Preincubation was carried out during 10 min at 37‡C.
Natural, synthetic tRNALys3 and tDNALys3 (1 WM) were prehybrid-
ized to the primer binding site of HIV RNA (1 WM) by heating 2 min
at 95‡C in the presence of 150 mM NaCl and slow cooling to 4‡C.
The four unlabeled dNTP precursors (200 WM each with HIV-2 RNA
or 100 WM each with HIV-1 RNA), and 100 WM extra dATP or dCTP
(respectively with HIV-2 or HIV-1 RNA) were then added and the
incubation was continued for variable times at 37‡C. When indicated
2.4 A260/ml poly(A)Woligo(dT) (corresponding to 1.6 WM of
oligo(dT)12ÿ18 primer) was used as a trap and added together with
the dNTPs to bind free RT. The reaction was stopped by addition of
3 Wl of gel loading bu¡er solution (10 mM Tris-HCl pH 8.0, 1 mM
EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol and 30% glycer-
ol) and the tubes were kept in ice. When the reaction was performed
in the presence of synthetic tRNALys3, we used a uniformly 32P-la-
beled tRNA, the yield of primer tRNA obtained by in vitro tran-
scription by T7 RNA polymerase being rather low. In this case, nei-
ther labeled dNTP nor any excess of cold dNTP was added during the
incubation. Reaction products were analyzed by electrophoresis on
6% polyacrylamide-TBE-7 M urea denaturing gels and autoradio-
graphed.
3. Results and discussion
Experiments performed in this work were designed to study
initiation during the ¢rst step of in vitro HIV-2 reverse tran-
scription, as well as the cDNA synthetic ability of HIV-2 RT
when using homologous or heterologous primer/template du-
plexes, involving natural or synthetic primers.
3.1. HIV-2 reverse transcription with RNA primers
Reverse transcription primed by tRNALys3 with HIV-2 RT
using HIV-2 RNA as template during di¡erent incubation
times is shown in Fig. 2. Two series of intermediate cDNA
bands corresponding to nucleotides +5 to +7 and +20 to +24
were observed between 15 s and 4 min of incubation (lanes 2^
6). The strong-stop band (377 nt) was visible at 10 min (lane
8) and its intensity was maximal at 45 min (lane 10) of in-
cubation. Interestingly, when poly(A)Woligo(dT) was used as a
trap (lanes 11^14), no strong-stop band was visible even after
45 min at 37‡C. Only three faint, but signi¢cant bands ap-
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Fig. 1. Schematic model of the secondary structure of the PBS re-
gion of HIV-2 RNA (adapted from [8]). The gray box corresponds
to the PBS sequence, the empty black box shows the A-rich region
5P of the PBS.
F. BoulmeŁ et al./FEBS Letters 430 (1998) 165^170166
peared at 15 s, corresponding to the incorporation of nucleo-
tides +1 to +5. These results are very similar to those de-
scribed in the HIV-1 homologous system [26], but in the latter
case the longest products observed in the presence of the trap
corresponded to the addition of three nucleotides (data not
shown). These results strongly suggest that the transition
process from initiation to elongation in the early phase of
reverse transcription is similar in HIV-1 and HIV-2 replica-
tion. As for HIV-1, the same molecule of HIV-2 RT is not
able to initiate cDNA synthesis from HIV-2 RNA and to
elongate it until the complete strong-stop band, as described
previously in the case of tRNALys3 primed homologous HIV-1
reverse transcription [27].
To further understand the mechanism of reverse transcrip-
tion by HIV-2 RT, we studied the initiation primed with syn-
thetic tRNALys3. This in vitro synthesized primer does not
have the modi¢ed bases present in native tRNALys3. By chem-
ical treatment of native tRNA leading to the conversion of a
modi¢ed thio-uridine into cytidine, as well as by other exper-
imental approaches, it has been reported that modi¢ed bases
may play an important role in the tRNALys3/HIV-1 RNA
interactions [12^14].
As shown in Fig. 3, HIV-2 RT was able to use synthetic
tRNALys3 as primer and the intensity of the strong-stop
cDNA band, which appeared after 7 min incubation (lane
7), increased regularly with time (lanes 8^10). However, no
elongation of the labeled primer was observed in the presence
of the poly(A)Woligo(dT) trap (lanes 11^14). Even the incorpo-
ration of 5^7 nucleotides observed with natural tRNALys3 did
not take place with the synthetic primer, suggesting that the
transition between initiation and elongation steps did not oc-
curred with the synthetic tRNALys3. The same result was ob-
served when a synthetic 18-mer ORN primer, complementary
to the PBS sequence (anti-PBS), was used (results not shown).
The data obtained with these two synthetic RNA primers
were di¡erent from those previously reported where +3 and
+5 nucleotide intermediate products were observed, but no
complete cDNA synthesis [27].
In our in vitro system, in the presence of the poly(A)Woli-
go(dT) trap, only the natural tRNALys3 was elongated by ¢ve
nucleotides on HIV-2 RNA (three bases on HIV-1 template,
see Fig. 5A), whereas the synthetic RNA primers were not
(Figs. 2 and 3). Our results (Figs. 2 and 3) support the hy-
pothesis that modi¢ed bases in natural tRNA are implicated
in the recognition of the primer-template duplex by RT, and
in a two-step mechanism in the early cDNA synthesis. How-
ever, the presence of post-transcriptional modi¢cations in nat-
ural tRNALys3, as well as the interaction between the antico-
don of the tRNA primer and the A-rich region of HIV-1
RNA, may not be necessary for the strong-stop cDNA syn-
thesis, since an anti-PBS ORN primer is e⁄ciently elongated
on HIV-1 and HIV-2 RNAs. It has been recently shown that
deletion of the A-rich loop present in the U5 region of HIV-1
RNA has no e¡ect on the elongation of the annealed
tRNALys3 [28]. Our results are supported by recent evidence,
including an elegant phylogenetic analysis, showing that a
signi¢cant level of reverse transcription was observed in a
murine leukemia virus [29] and in a SIV [30] in the absence
of interaction between the anticodon of the tRNA primer and
the A-rich region 5P to the PBS.
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Fig. 2. Reverse transcription by HIV-2 RT of HIV-2 RNA template
primed by tRNALys3, in the presence or absence of a trap poly(A)Wo-
ligo(dT). A: Schematic representation of the expected size of full-
length cDNA from tRNALys3 primer. B: The reaction products
were analyzed by gel electrophoresis as described in Section 2.
Lanes 1^10: respectively, 0, 15 s, 30 s, 1, 2, 4, 7, 10, 30 and 45 min
of incubation starting with the dNTPs; lanes 11^14: 0, 15 s, 10 and
45 min at 37‡C starting with the dNTPs mixture and a poly(A)Woli-
go(dT) trap. Labeled 1 kb DNA ladders were used as size markers.
Fig. 3. Reverse transcription of HIV-2 RNA template by the ho-
mologous RT and a synthetic tRNALys3 as primer. Same conditions
as Fig. 2 were used. A similar result was obtained when a non-la-
beled synthetic tRNALys3 was used in the same conditions described
for natural tRNA primer.
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3.2. HIV-2 reverse transcription with DNA primers
Compared to natural tRNA primer, a faster rate of cDNA
synthesis was obtained (Fig. 4) when the reaction was primed
by synthetic tDNALys3, a molecule which is also devoid of
modi¢ed bases. Similar results were obtained with a synthetic
anti-PBS ODN. In the presence of these DNA synthetic pri-
mers, only 15 s were necessary to obtain an important cDNA
band of about 100 nucleotides from HIV-2 RNA (45 nt in the
case of HIV-1 template). Moreover, in reverse transcription
primed by DNA, only a low decrease in the cDNA synthesis
e⁄ciency was observed in the presence of the poly(A)Woli-
go(dT) trap, showing that the same RT molecule was able
to initiate and elongate the DNA primer without any transi-
tion step. Thus with DNA primers, initiation resulted from a
non-speci¢c mechanism. Similar conclusions have been re-
ported previously, showing that ODN primers are very e⁄-
ciently elongated by heterologous RTs [27].
Can the di¡erences found between RNA or DNA primers
be explained only by the a⁄nity between RT and primer?
Data obtained with HIV-1 RT showed that the enzyme pre-
sented a similar high a⁄nity for anti-PBS ODN and natural
tRNA primers, even if the observed processivity was very
di¡erent [19]. In contrast, a low a⁄nity of HIV-1 RT for
synthetic RNA primers (anti-PBS ORN or synthetic
tRNALys3) was reported. However, gel retardation experi-
ments and £uorescence determination showed similar a⁄nities
of HIV-1 RT towards the natural and synthetic tRNALys3
[31,32]. To explain our results, we can hypothesize that the
conformation of the primer/template heteroduplex involving a
DNA primer in interaction with HIV RT is di¡erent from the
RNA/RNA natural duplex. This can be correlated to our
previous data on cDNA synthesis using synthetic primer/tem-
plate duplexes and HIV-1 RT [33]. Our results concerning
riboprimers and deoxyriboprimers demonstrated a reverse
correlation between the primer a⁄nity and the rate of DNA
synthesis. In the presence of a synthetic RNA template, while
riboprimers presented a high a⁄nity for HIV-1 RT, deoxyri-
boprimers gave the faster polymerization rate. Analysis of the
binding and elongation of various template/primer duplexes
showed that the optimal conformation of a template/primer
for HIV-1 RT takes place when the template presents an A-
like chain conformation (RNA) and the primer a B-like chain
conformation (DNA) in the duplex. In this case a higher
a⁄nity and translocation rate is favored.
Furthermore, recent results showed that most (s 95%) of
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Fig. 5. Heterologous in vitro reverse transcription in the presence of natural primer tRNALys3. A: cDNA synthesis by HIV-2 RT on HIV-1
RNA. Lanes 1^10: respectively, 0, 15 s, 30 s, 1, 2, 4, 7, 10, 30 and 45 min of incubation with the dNTPs. B: Reverse transcription by HIV-1
RT of HIV-2 RNA template. Identical incubation times as A were used.
Fig. 4. Reverse transcription from a synthetic tDNALys3 primer in a
homologous HIV-2 in vitro system. Lanes 1^5: respectively, 0, 15 s,
1, 7 and 45 min of incubation at 37‡C. Lanes 6^9: 15 s, 1, 7 and
45 min of incubation in the presence of the trap.
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the virion-extracted tRNA/viral RNA duplexes were found to
be already elongated in HIV-2 and HIV-1 particles, implying
that partial cDNA synthesis may take place in intact virions
[26,34]. They suggested that extended tRNALys3 could be
more e⁄ciently elongated by the RT enzyme, since its 3P
end corresponds to a DNA primer, which is characterized
by a fast elongation. This could explain the di¡erences ob-
served between the distributive initiation and the fully proc-
essive elongation steps, only observed in natural tRNALys3
primed reverse transcription.
3.3. Reverse transcription in a heterologous system
As mentioned above, both the initiation and elongation
steps seem to operate in a similar way in HIV-1 or HIV-2
homologous cDNA synthesis systems. In the case of a heter-
ologous system, however, previous reports showed that HIV-2
RT was unable to copy a HIV-1 RNA template in a natural
tRNALys3 primed reverse transcription reaction [20]. We ad-
dressed the question whether there will be heterologous re-
verse transcription in our experimental conditions. Results
from Fig. 5A show that reverse transcription initiated by
HIV-2 RT from a tRNALys3 primer, using a HIV-1 RNA
fragment corresponding to the 5P retroviral genome as tem-
plate, was very e⁄cient. In this in vitro heterologous system,
the 253 nt strong-stop cDNA was obtained after 10 min of
incubation (lane 8). Incorporation of nucleotides +3 to +5
and faint intermediate bands were also visualized. Similarly,
an e⁄cient tRNALys3 primed cDNA synthesis reaction using a
HIV-2 RNA template and HIV-1 RT was observed ([26] and
Fig. 5B). As both enzymes, HIV-1 and HIV-2 RTs, present
similar processivity on the same template (Figs. 2 and 5B), we
can assumed that the cDNA ‘pausing’ bands are due to the
secondary structure of the template, rather than to di¡erences
in the processivity of the two retroviral enzymes.
Thus, the results presented here show that HIV-2 RT was
able to reverse transcribe both HIV-1 and HIV-2 RNA at
similar rates. This is in contradiction with previously reported
data [20] where it was suggested that the inability to synthe-
size cDNA was related to a C-terminal deletion in the small
subunit of the HIV-2 RT recombinant form [35]. However,
using the same recombinant construction described in [21], i.e.
an RT with a p54 subunit of 439 amino acids, we observed a
signi¢cant elongation from natural tRNALys3 on HIV-2 or
HIV-1 RNA templates (Figs. 2 and 5, respectively). Similar
results were obtained when we used di¡erent forms of HIV-1
and HIV-2 RTs, RNase H (+) or (3). Moreover, a p66/p66
homodimer HIV-1 RT was also able to elongate tRNALys3 on
HIV-1 RNA (results not shown).
In conclusion, two original observations have been de-
scribed in this work. First, we showed that initiation of
HIV-2 reverse transcription is a speci¢c process with a tran-
sition between initiation and elongation. The mechanism is
very similar to that reported for HIV-1. Both HIV-1 and
HIV-2 share the same primer tRNA and possess an A-rich
region 5P to the PBS sequence. Such an interaction between
tRNALys3 and HIV-2 RNA has only been suggested [8,12,30].
Work is in progress using the antisense strategy on the A-rich
mutated HIV-2 RNA region in order to obtain further proof
of this interaction. Second, in contrast to previous reports
[20], we showed that the HIV-1 RNA/tRNALys3 complex
was e⁄ciently extended not only by the homologous HIV-1
RT, but also by a heterologous enzyme, HIV-2 RT.
Experiments designed to obtain a better understanding of
the mechanism of HIV cDNA initiation synthesis seem very
important to set up an e⁄cient inhibitory strategy to block
this key step of the retroviral replication cycle.
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